Nadir CA-125 Level Is an Independent Prognostic Factor in Advanced Epithelial Ovarian Cancer

被引:23
|
作者
Kang, Sokbom [1 ]
Seo, Sang-Soo [1 ]
Park, Sang-Yoon [1 ]
机构
[1] Natl Canc Ctr, Res Inst & Hosp, Branch Uterine Canc, Goyang 411769, South Korea
关键词
ovarian cancer; CA-125; cytoreductive surgery; prognostic factor; progression free survival; GYNECOLOGIC-ONCOLOGY-GROUP; CA125; CONCENTRATION; THERAPY; CHEMOTHERAPY; PACLITAXEL; CARCINOMA; SURVIVAL; PLATINUM; SURGERY; TRIAL;
D O I
10.1002/jso.21258
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: The purpose of this study was to determine the independency of a nadir CA-125 level as a prognostic factor in patients with advanced epithelial ovarian cancer (EOC). Methods: Among the 153 women with advanced EOC who had surgery in our hospital between January 2001 and June 2007, 121 women underwent retrospective chart review. Results: Sixty-six patients (57.9%) had nadir CA-125 values <= 10 U/ml. The CA-125 levels at the time of diagnosis was associated with the nadir CA-125 (P = 0.018). The median progression-free survival (PFS) in patients with nadir CA-125 levels <= 10 and 10-35 U/ml was 32.4 and 16.8 months, respectively (P = 0.0001). A multivariate Cox hazard model revealed that the nadir CA-125 value and the residual tumor size >= 0.5 cm were independently associated with the PFS (P = 0.001 and 0.014). Within the subgroup who underwent primary debulking surgery, the significant association between the PFS and the nadir CA-125 value was preserved (P = 0.001). Conclusions: The prognostic role of the nadir CA-125 is independent of residual tumor size in the patients with advanced EOC. However, it is still unclear whether maximal surgical effort can affect the nadir CA-125 levels. J. Surg. Oncol. 2009;100:244-247. (C) 2009 Wiley-Liss, Inc.
引用
收藏
页码:244 / 247
页数:4
相关论文
共 50 条
  • [21] THE PROGNOSTIC VALUE OF POST CHEMOTHERAPY SERUM CA-125 IN EPITHELIAL OVARIAN-CANCER
    TEELING, M
    MCGING, P
    CARNEY, DN
    IRISH JOURNAL OF MEDICAL SCIENCE, 1989, 158 (03) : 59 - 62
  • [22] Interaction between preoperative CA-125 level and survival benefit of neoadjuvant chemotherapy in advanced epithelial ovarian cancer
    Kang, Sokbom
    Kim, Tae-Joong
    Seo, Sang-Soo
    Kim, Byoung-Gie
    Bae, Duk-Soo
    Park, Sang-Yoon
    GYNECOLOGIC ONCOLOGY, 2011, 120 (01) : 18 - 22
  • [23] Preoperative serum CA-125 level as a predictor for the extent of cytoreduction in patients with advanced stage epithelial ovarian cancer
    Merlo, Sebastjan
    Besic, Nikola
    Drmota, Eva
    Kovacevic, Nina
    RADIOLOGY AND ONCOLOGY, 2021, 55 (03) : 341 - 346
  • [24] CA-125 MEASURED BEFORE 2ND-LOOK LAPAROTOMY IS AN INDEPENDENT PROGNOSTIC FACTOR FOR SURVIVAL IN PATIENTS WITH EPITHELIAL OVARIAN-CANCER
    MAKAR, AP
    KRISTENSEN, GB
    BORMER, OP
    TROPE, CG
    GYNECOLOGIC ONCOLOGY, 1992, 45 (03) : 323 - 328
  • [25] Serum CA-125 level after 6 cycles of primary adjuvant chemotherapy is a useful prognostic factor for complete responders' survival in patients with advanced epithelial ovarian cancer
    Kim, Hee Seung
    Park, Noh-Hyun
    Chung, Hyun Hoon
    Kim, Jae Weon
    Song, Yong-Sang
    Kang, Soon-Beom
    ONKOLOGIE, 2008, 31 (06): : 315 - 320
  • [26] Nadir CA125 concentration as a prognostic indicator in ovarian cancer
    Baron, AT
    Maihle, N
    NATURE CLINICAL PRACTICE ONCOLOGY, 2005, 2 (06): : 288 - 289
  • [27] Nadir CA125 concentration as a prognostic indicator in ovarian cancer
    Andre T Baron
    Nita Maihle
    Nature Clinical Practice Oncology, 2005, 2 : 288 - 289
  • [28] CA-125 AUC as a predictor for epithelial ovarian cancer relapse
    Manoa, Antonio
    Falcao, Amilcar
    Godinho, Isabel
    Santos, Jorge
    Leitao, Fatima
    de Oliveira, Carlos
    Caramona, Margarida
    CANCER BIOMARKERS, 2008, 4 (02) : 73 - 81
  • [29] CA-125 as response criterion in patients with epithelial ovarian cancer
    Zirpel, I
    Illiger, HJ
    STRAHLENTHERAPIE UND ONKOLOGIE, 2000, 176 (04) : 200 - 200
  • [30] Assessment of CA-125 area under the curve as a prognostic factor in patients with ovarian cancer
    Sernaz Uzunoglu
    Aysun Aybatlı
    Petek Balkanlı Kaplan
    Irfan Cicin
    Necdet Sut
    Cenk Sayın
    Fusun Varol
    Medical Oncology, 2013, 30